Financials

Company Profile

Scorpius Holdings, Inc. is not engaged in any business activities. The Company was previously a contract development and manufacturing organization.

Employees

Sector

Date	Price	Change	Volume
22/07/26	USD 0.000400	-66.67%	200
21/07/26	USD 0.001200	-.--%	504

Real-time OTC Markets

Real-time OTC Markets Other stock markets 12:29:25 04/06/26 am AEST			5-day change	1st Jan Change
0.001400 ^USD	+7.69%		+250.00%	+600.00%

25/04	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
08/04	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI

25/04	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
08/04	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI
11/03	Scorpius Holdings, Inc. announced that it has received $0.031175 million in funding	CI
26/02	Scorpius Holdings, Inc. announced that it has received $0.219544 million in funding	CI
18/02	Scorpius Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/02	Scorpius Holdings, Inc. announced that it has received $0.030427 million in funding	CI
13/01	Scorpius Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
16/12	Scorpius Holdings, Inc. announced that it has received $0.044374 million in funding	CI
11/12	Velocity Bioworks, Inc. acquired All of Personal Property and Assets of Scorpius Holdings, Inc. for $16.3 million.	CI
03/12	Scorpius Holdings, Inc. Announces Issuance of Multiple Non-Convertible Promissory Notes with Customary Terms	CI
01/12	Scorpius Holdings, Inc. announced that it has received $0.1541 million in funding	CI
26/11	Scorpius Holdings, Inc. announced that it has received $0.724523 million in funding	CI
25/11	Scorpius Holdings, Inc. announced that it has received $0.03795 million in funding	CI

02/05/23	Brookline Capital Downgrades NightHawk Biosciences to Hold From Buy	MT
03/04/23	Maxim Downgrades NightHawk Biosciences to Hold From Buy	MT
19/03/22	B. Riley Lowers Heat Biologics' PT to $8 from $10, Adjusts Model for Higher Cost of Capital to Support Higher Operating Expenditures Ramp; Keeps Buy Rating	MT
16/03/22	Alliance Global Adjusts Heat Biologics' Price Target to $15.50 From $20, Reiterates Buy Rating	MT
25/01/22	B. Riley Lowers Heat Biologics' Price Target to $10 from $15 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT

13/01	Scorpius : Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)	PU
15/11/24	Scorpius : Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability Form 8 K	PU
22/10/24	Scorpius Holdings Announces Partnership with U.S. Biotech Company	AQ
02/10/24	Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats	AQ
30/09/24	Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities	AQ

Manager	Title	Age	Since
Jeff Wolf CEO	Chief Executive Officer	63	01/04/2010
Joe Payne COO	Chief Operating Officer	-	-
David Waldman IRC	Investor Relations Contact	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/5/24	Jeff Wolf	Free	Chief Executive Officer	5,000,000	13.8766%
16/5/24	Seed-One Ventures LLC	Other	Company	0	0%
16/5/24	Orion Holdings LLC	Other	Company	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCORPIUS HOLDINGS, INC.	+7.69%	+250.00%	-87.27%	-100.00%	24.46K
BOXABL INC.	-7.93%	-18.36%	-49.70%	-	14.94B
FREENOME, INC.	+1.94%	-23.44%	-4.82%	-	1.14B
CHURCHILL CAPITAL CORP XI	+4.55%	-2.29%	-	-	753M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	+0.30%	-	-	645M
CHURCHILL CAPITAL CORP XII	+0.94%	-1.48%	-	-	607M
CENTIEL AG	+1.32%	-5.81%	+272.88%	-68.57%	605M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.20%	+0.01%	-	-	597M
CANTOR EQUITY PARTNERS IV, INC.	-0.24%	-0.53%	-	-	596M
Average	+0.93%	-4.56%	+32.77%	-84.29%	2.21B
Weighted average by Cap.	-5.61%	-7.38%	-34.94%	-68.57%